Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT05484882 Completed - Heart Disease Clinical Trials

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

Start date: February 18, 2023
Phase:
Study type: Observational

Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play.

NCT ID: NCT05480709 Completed - Clinical trials for Cardiovascular Diseases

Evaluation of Immediate and Medium-term Health- and Work-related Effects Following Inpatient Psychocardiological Rehabilitation

EvalPsyKard
Start date: May 3, 2021
Phase:
Study type: Observational

Since May 2019, psychocardiological rehabilitation has been carried out at the Rehabilitation Center Felbring (RFE) in the form of a pilot project. The background is the mutual relationship of psychological and physical morbidity, which is of particular importance in cardiological rehabilitation. The present outcome evaluation study is designed as a quantitative longitudinal study with 4 repeated measures, in which at least 75 rehabilitation patients will be included. Three assessments are conducted at admission and discharge to/from inpatient rehabilitation, and an additional survey will be conducted by mail 6 months after the end of rehabilitation. Effects that become apparent as a result of rehabilitation will be recorded from a patient-centered perspective by means of "patient-reported outcomes". In this way, primarily psychological and work-related changes, but also changes in the physical quality of life are to be mapped, which can be determined immediately after completion of rehabilitation and continue in the medium term up to 6 months later.

NCT ID: NCT05479331 Completed - Clinical trials for Cardiovascular Diseases

The Relationship Between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease and the Risk Involved.

Start date: January 1, 2020
Phase:
Study type: Observational

This study explores the risk factors for sarcopenia in patients with chronic kidney disease and the effects of sarcopenia on cardiovascular disease. Treatment of sarcopenia and cardiovascular complications provides a basis for improving the quality of life and survival of patients with chronic kidney disease.

NCT ID: NCT05474053 Completed - Clinical trials for Cardiovascular Diseases

Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

Start date: November 13, 2021
Phase: Phase 3
Study type: Interventional

This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. we advocate comparing the clinical efficacy rather than simple bioequivalence comparison.

NCT ID: NCT05472454 Completed - Hypertension Clinical Trials

The Ready-to-Eat Meals for Cardiovascular Health Study

REACH
Start date: October 7, 2022
Phase: N/A
Study type: Interventional

The proposed project explores the acceptability and health benefits of ready-to-eat (RTE) meals based on the Dietary Approaches to Stop Hypertension (DASH) eating plan. The researchers have developed 14 recipes following the DASH eating plan, which is recommended for the prevention of cardiovascular disease (CVD). The prepackaged meals will be processed using Washington State University (WSU) microwave technologies to ensure food safety. In this pilot study, a sample of 30 participants will be recruited by to study the impact of the DASH meals on blood pressure. All meals will be provided to participants, who will consume the meals daily over a period of 4 weeks. Daily and weekly monitoring of participants (blood pressure and weight) will allow us to gain a scientific understanding on the preventive power of healthy diets in lowering blood pressure and reducing CVD risk.

NCT ID: NCT05466825 Completed - Stroke Clinical Trials

Global Cardiovascular Risk Consortium

Start date: September 20, 2019
Phase:
Study type: Observational

The Global Cardiovascular Risk Consortium (GCVRC) comprises harmonized data from nearly 1.7 Mio individuals of 126 cohorts across 43 countries and aims to elucidate the distribution of five major cardiovascular risk factors (body mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes) and their impact on cardiovascular disease (CVD) by geographical region and sex.

NCT ID: NCT05454930 Completed - Clinical trials for Cardiovascular Diseases

Effect of Commute Traffic on Vascular Function

Start date: January 2015
Phase: N/A
Study type: Interventional

The investigators will assess the vascular effects of riding in a car in heavily trafficked roadways, and whether filtering the car's air reduces those effects.

NCT ID: NCT05449652 Completed - Clinical trials for Cardiovascular Diseases

Exercise Prescriptions for Patients With Cardiovascular Disease

Start date: February 16, 2022
Phase:
Study type: Observational

Physiotherapists are often confronted with patients with (elevated risk for) cardiovascular disease (CVD), even when this is not the primary indication for physiotherapy. Hence, physiotherapists should be able to provide evidence-based exercise advice to these patients, but this has not been assessed. The aim of this study was therefore to assess whether exercise prescriptions by physiotherapists to patients with CVD are in accordance with international recommendations.

NCT ID: NCT05437094 Completed - Heart Failure Clinical Trials

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Start date: June 27, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study site until discharge on Day 16. Subjects will receive CRD-740 orally on Days 1 and 10. Itraconazole will be given once daily, orally, on Days 7 through 15.

NCT ID: NCT05431894 Completed - Clinical trials for Cardiovascular Diseases

Behavioral and Recovery Support for 30 Day Post-Discharge Care

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

This study will provide behavioral and mental health support to a select group of participants to supplement the hospital-provided discharge and recovery plans, based on clinical guidance and dedicated post-hospitalization behavioral protocols, with the goals of reducing readmission rates and costs.